Acasti Pharma to schedule second quarter FY2022 business update conference call


The call will take place on Wednesday, November 10 at 1 p.m. EST

LAVAL, Quebec, Nov. 04, 2021 (GLOBE NEWSWIRE) – Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), today announced that it will hold a conference call at 1:00 p.m. EST on Wednesday, November 10, 2021 to discuss company progress and other developments, as well as financial results for the second quarter of fiscal 2022 ended September 30, 2021 .

The conference call will be available by telephone by dialing the toll-free number 877-545-0523 for US callers or +1 973-528-0016 for international callers and using the entry code 948112. A webcast from the call can be viewed at or on the Company’s Investor Relations section of the website:

A replay of the webcast will be available in the Company News / Events section of the website ( until November 10, 2022. A telephone replay of the call will be available approximately one hour after the call, until November 17, 2021, and can be viewed by dialing 877-481-4010 for US callers or +1 919-882-2331 for international callers and incoming conference ID: 43383.

About Acasti
Acasti is an advanced stage specialty pharmaceutical company with drug delivery technologies and drug candidates for the treatment of rare and orphan diseases. Acasti’s new drug delivery technologies have the potential to improve the performance of currently marketed drugs by achieving faster onset of action, increased efficacy, reduced side effects, and more convenient drug delivery, all which could help increase treatment adherence and improve patient outcomes.

Acasti’s three primary clinical assets have each received orphan drug designation from the FDA, giving them seven years of marketing exclusivity after launch in the United States and additional intellectual property protection with over 40 patents granted and pending. Acasti’s main clinical assets target underserved orphan diseases: (i) GTX-104, an intravenous infusion targeting subarachnoid hemorrhage (HSA), a rare and life-threatening medical emergency in which bleeding occurs on the surface of the brain in the subarachnoid space between the brain and skull; (ii) GTX-102, an oral mucosa spray targeting ataxia-telangiectasia (AT), a progressive neurodegenerative genetic disease which mainly affects children, causing severe disability, and for which no treatment currently exists; and (iii) GTX-101, a topical spray targeting postherpetic neuralgia (NPH), a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella-zoster virus (shingles), which can persist for months or even years. For more information, please visit:

Forward-looking statements
Statements in this press release that are not statements of historical or current fact constitute “forward-looking information” within the meaning of Canadian securities laws and “forward-looking statements” within the meaning of the US Private Securities Litigation Reform Act. of 1995, as amended, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, “forward-looking statements”). These forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause Acasti’s actual results to differ materially from historical results or from any future results expressed or implied by these forward-looking statements. In addition to statements which explicitly describe these risks and uncertainties, readers are encouraged to consider statements containing the terms “belief”, “belief”, “expect”, “intention”, “anticipate”, “Possible”, “should”, “may”, “will”, “plans”, “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

The forward-looking statements contained in this press release are based on Acasti’s current expectations and involve assumptions which may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties, including, without limitation: (i) the success and timing of the study’s regulatory submissions PK transition for GTX -104 and other Acasti preclinical and clinical trials; (ii) regulatory requirements or developments; (iii) changes in clinical trial design and regulatory pathways; (iv) legislative, regulatory, political and economic developments, and (v) the effects of COVID-19 on clinical programs and business operations. The foregoing list of important factors which could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with the statements which are included herein and elsewhere, including the detailed risk factors. in documents which have been and may be filed by Acasti from time to time with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Acasti assumes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by applicable securities laws.

Neither NASDAQ, TSXV nor its Regulation Services Provider (as that term is defined in the policies of TSXV) accepts responsibility for the adequacy or accuracy of this release.

Acasti contact:
Jan D’Alvise
Chief Executive Officer
Phone. : 450-686-4555
E-mail: [email protected]

Investor contact:
Crescendo Communications, LLC
Phone. : 212-671-1020
E-mail: [email protected]

Media contact:
Jules Abraham
JQA Partners, Inc.
Phone. : 917-885-7378
E-mail: [email protected]

Source link


Comments are closed.